However, given the heterogeneity of CD28− CD8+ T cells (i.e., production of cytotoxic or immunosuppressive factors), which depends on both the cancer type and the individual genetic background, their contribution to the tumor progression and the impact on a specific immune-strategy are unpredictable [14]. The gene discussed is CD8A; the disease is neoplasm.